Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Tax Provisions (2024 - 2025)

Indivior Pharmaceuticals has reported Tax Provisions over the past 2 years, most recently at -$21.0 million for Q4 2025.

  • Quarterly results put Tax Provisions at -$21.0 million for Q4 2025, down 223.53% from a year ago — trailing twelve months through Dec 2025 was $29.0 million (up 123.08% YoY), and the annual figure for FY2025 was $29.0 million, up 123.08%.
  • Tax Provisions for Q4 2025 was -$21.0 million at Indivior Pharmaceuticals, down from -$5.0 million in the prior quarter.
  • Over the last five years, Tax Provisions for INDV hit a ceiling of $44.0 million in Q2 2025 and a floor of -$23.0 million in Q2 2024.